• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: End of beginning or beginning of end?
【24h】

Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: End of beginning or beginning of end?

机译：基于淀粉样蛋白的免疫疗法治疗阿尔茨海默氏病的临床试验：是开始还是结束？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Amyloid deposit and hyperphosphorylated Tau protein contribute to pathological changes seen in Alzheimer's disease (AD) and imply that removal may reverse the cognitive decline. Immunotherapy is a potential way of reducing the load of amyloid or Tau in the brain. Areas covered: This review summarizes recent clinical trials that have investigated immunotherapy to treat AD and its potential mechanisms. In addition, the potential opportunities as well as challenges of immunotherapy for AD in clinical trials are also discussed. Expert opinion: Amyloid-based immunotherapy for AD is a novel method with potential; however, some clinical trials were terminated because of the adverse effects. Further studies need to determine the following questions: (i) which is better, passive, or active immunotherapy; (ii) which could be used for the vaccine, amyloid or Tau; (iii) which is better, short- or long-antigen vaccine; and (iv) the route of delivery for antigen or antibody.
机译：简介：淀粉样蛋白沉积和高磷酸化的Tau蛋白有助于阿尔茨海默氏病（AD）的病理变化，暗示去除可能会逆转认知功能下降。免疫疗法是减少大脑中淀粉样蛋白或Tau负荷的潜在方法。涵盖领域：这篇综述总结了最近的临床试验，该临床试验研究了免疫疗法治疗AD及其潜在机制。此外，还讨论了在临床试验中针对AD进行免疫疗法的潜在机会和挑战。专家意见：基于淀粉样蛋白的AD免疫疗法是一种具有潜力的新型方法。然而，由于不良反应，一些临床试验被终止。进一步的研究需要确定以下问题：（i）哪种是更好的，被动的或主动的免疫疗法; （ii）可用于疫苗，淀粉样蛋白或Tau的疫苗; （iii）更好的短抗原或长抗原疫苗; （iv）抗原或抗体的递送途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号